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Objective: To investigate the associations between hypovitaminosis D and disease
activity in a cohort of relapsing remitting multiple sclerosis (RRMS) and clinically isolated
syndrome (CIS) patients.
Methods: In 51 RRMS and 2 CIS patients on stable interferon-β-1b (IFN-β-1b) treatment
recruited to the EVIDIMS study (Efficacy of Vitamin D Supplementation in Multiple
Sclerosis (NCT01440062) baseline serum vitamin D levels were evaluated. Patients were
dichotomized based on the definition of vitamin D deficiency which is reflected by a < 30
vs. ≥ 30 ng/ml level of 25-hydroxyvitamin D (25(OH)D). Possible associations between
vitamin D deficiency and both clinical and MRI features of the disease were analyzed.
Results: Median (25, 75% quartiles, Q) 25(OH)D level was 18 ng/ml (12, 24). Forty
eight out of 53 (91%) patients had 25(OH)D levels < 30 ng/ml (p < 0.001). Patients with
25(OH)D ≥ 30 ng/ml had lower median (25, 75% Q) T2-weighted lesion counts [25 (24,
33)] compared to patients with 25(OH)D < 30 ng/ml [60 (36, 84), p = 0.03; adjusted for
age, gender and disease duration: p < 0.001]. Expanded disability status scale (EDSS)
score was negatively associated with serum 25(OH)D levels in a multiple linear regression,
including age, sex, and disease duration (adjusted: p < 0.001).
Interpretation: Most patients recruited in the EVIDIMS study were vitamin D deficient.
Higher 25(OH)D levels were associated with reduced T2 weighted lesion count and lower
EDSS scores.
Keywords: multiple sclerosis, vitamin D, vitamin D deficiency, T2w lesion count, EDSS score, disease severity,
EVIDIMS
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INTRODUCTION
The exact cause of multiple sclerosis (MS), a chronic
inflammatory and neurodegenerative autoimmune disease
of the central nervous system (1) is unknown. However, several
environmental and genetic factors have been associated with
MS pathogenesis, among them are vitamin D (VD) serum levels
(2–5), vitamin D receptor polymorphisms (VDP) (6–10), and
sunlight exposure (11, 12). In fact, increasing evidence suggests
that VD deficiency may affect disease progression and outcome
in MS.
VD is considered a potent immunomodulator which
may reduce MS risk based on epidemiological and
experimental evidence (13–15). High serum VD levels have
been associated with lower MS risk, reduced relapse rates
(16) and better disease outcome (2, 13, 17). Circulating
VD levels are lower during relapses compared to phases
of disease stability (18). In vitro studies also showed
a reduced proliferation of CD4+ T cells and myelin
basic protein (MBP)-specific T cells in the presence of
1,25(OH)D3, the active metabolite of vitamin D (18). The
immunomodulatory effect of vitamin D in upregulating
anti-inflammatory cytokines points to an important role
in the homeostasis of T cells (18) hence its relevance in
autoimmune diseases.
The high prevalence of hypovitaminosis D worldwide (19, 20)
and the continuously increasing incidence of MS incidence (21)
highlights the need to investigate possible associations.
The American Institute of Medicine (IOM) (22), the Japan
Endocrine Society (23), the Osteoporosis Council of Canada
(24), and the International Osteoporosis Foundation (25)
have suggested divergent cut-offs for vitamin D deficiency
ranging from < 20 to < 30 ng/ml. These definitions are
mainly based on the prevention of osteoporosis (22, 23,
26–28). In healthy populations, serum vitamin D levels
≥ 30 ng/ml are considered sufficient (29–31). In the past
decade, several clinical interventional trials have investigated
the effect of vitamin D supplementation on the pathogenesis
of MS, among them the EVIDIMS (NCT01440062) (32),
the SOLAR (33), the VIDAMS (34), and the CHOLINE
trials (35). Moreover, data from observational studies suggest
that there may be a beneficial interaction of vitamin D
and interferon-β regarding their immunomodulatory effect
(36, 37).
In this paper, we dichotomized patients enrolled in the
EVIDIMS study at baseline prior to randomization and
vitamin D supplementation according to their serum 25(OH)D
levels and based on VD deficiency. We then investigated
possible associations of the VD status with clinical and MRI
parameters. The EVIDIMS study investigated the effect of oral
VD supplementation on clinical and MRI parameters in MS
patients on stable immunomodulatory interferon-β treatment.
The primary outcomes of the EVIDIMS trial are presented
elsewhere (38). The goal of this analysis is to investigate if
the EVIDIMS cohort is representative of a VD deficient RRMS
cohort by (a) investigating VD serum levels and (b) investigating
correlations with disease severity.
METHODS
Patients
The cohort in this study represents the baseline cohort of
phase II interventional EVIDIMS trial (NCT01440062) (32)
and comprised 51 patients with RRMS and 2 CIS patients, all
Caucasians, according to the 2005 McDonald criteria (39). The
detailed in- and exclusion criteria for the EVIDIMS trials have
been published earlier (32, 38). Briefly, inclusion criteria were
age of 18-65 years, Expanded Disability Status Score (EDSS)
below 6.5, stable interferon-β-1b treatment for a minimum of
3 months, freedom of relapses for at least 30 days prior to
study entry, and a relapsing remitting disease course or CIS.
The exclusion criteria were other immunomodulatory therapies
than interferon-β-1b, VD intake within 6 months before study
entry, pregnancy or lactation and kidney disease, bone marrow
dysfunction or hypercalcemia. To account for sunlight intensity
as a possible confounder, patients were recruited from a single
geographic region in the north-eastern part of Germany.
Disability was evaluated using EDSS scores. All clinical and
MRI assessments were performed blinded to serum VD status.
Measurement of Serum 25(OH)D Levels
Serum 25(OH)D levels were measured by the Bioscientia
Institute for Medical Diagnostics GmbH (Berlin, Germany)
using the LIAISON R© chemiluminescence analyzer, DiaSorin
(Dietzenbach, Germany).
Definitions of Groups
Subgroup analyses based on serum 25(OH)D levels were
performed based on the suggested cut-offs for VD levels for bone
health as proposed by the American Institute of Medicine, the
Japan Endocrine Society and the global definition for vitamin
D deficiency and sufficiency. Hence, dichotomous analyses
comparing serum 25(OH)D levels of (< 30 vs. ≥ 30 ng/ml) were
performed. These groups were compared with respect to the
following (i) MRI imaging parameters: T2 weighted lesion count
(T2C), T2 lesion volume (T2V), white matter volume (WM),
gray matter volume (GM), total brain volume and (ii) clinical
parameters such as EDSS scores.
MRI Protocol
The same MRI machine and protocol were used in all patients
using a Magnetom TIM TRIO 3 Tesla MRI (Siemens,
Healthineers, Erlangen, Germany). High resolution images
were acquired using a sagittal three-dimensional (3D) T2-
weighted (T2w) SPACE sequence (repetition time (TR) ms /echo
time (TE) ms/ inversion time (TI) ms (5,000/502/900; flip angle
9
◦
/, isotropic resolution 1 mm3, Generalized Autocalibrating
Partially Parallel Acquisition (GRAPPA 2), a 3D SPACE-FLAIR
(TR ms/TE ms/ TI ms, 6,000/388/2,100) with similar spatial
parameters and a three-dimension (3D) T1w, magnetization-
prepared rapid gradient-echo (MP-RAGE) sequence (TR
ms/echo time ms/ TI ms, 1,900/3.03/900; flip angle 9
◦
, isotropic
resolution 1 mm3, GRAPPA 2). Five minutes after injection of
0.1 mmol/kg gadolinium-labeled diethylenetriaminepentaacetic
acid (Gd-DTPA, Magnevist, Bayer-Schering, Berlin, Germany), a
3D T1w gradient recall echo volumetric interpolated breath-hold
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examination (VIBE) sequence (TR ms/TE ms, 4.8/2.2; flip
angle 9
◦
, isotropic resolution 1 mm3, GRAPPA 2) was applied.
The quality of acquired images was reviewed, and raw data
were transferred to a Linux workstation and processed semi-
automatically using an image coregistration (FMRIB’s Linear
Image Registration Tool, FMRIB Analysis Group, University
of Oxford, Oxford, UK) and inhomogeneity correction routine
embedded into the MedX v.3.4.3 software package (Sensor
Systems Inc., Sterling, VA, USA).
The MedX v.3.4.3 software package was used for measuring
the white matter lesion load and lesion count of T2w scans,
the number and volume of contrast-enhancing and hypointense
lesions on T1w scans. Segmentation of brain lesions was
performed semi-automatically using the lesion segmentation
toolbox (LST) (40) lesion probability algorithm on FLAIR
images with subsequent manual correction using ITK-SNAP
(41). Normalized brain volume (NBV) and percentage brain
volume change (PBVC) were obtained with SIENA (FMRIB
library) (40).
Statistical Analyses
Results for continuous variables are expressed as median with
25 and 75% quartiles [25, 75%] for non-normally distributed
data and as mean ± standard deviation (SD) for age and
disease duration. Results for categorical variables are given as
absolute numbers and relative frequencies (%). Due to the non-
normally distributed continuous data and small sample sizes,
exact Mann–Whitney U-test was used for the comparison of
independent groups. Simple linear regression analyses were used
for the association between EDSS and serum vitamin D levels.
Multivariate linear regressions were applied in order to adjust
this association for possible confounding factors such as age,
disease duration, and sex. We also tested for collinearity between
the independent variables. Non-parametric analysis of covariance
was applied to test T2-weighted lesion counts and volume for
differences between groups of vitamin D sufficiency (< 30 vs.
≥ 30 ng/ml), adjusted for the covariates age, gender, and disease
duration. A p-value of < 0.05 was considered significant. All
other tests should be understood as constituting exploratory data
analysis, such that no adjustments for multiple testing have been
made. Statistical analyses were performed in R version 3.4.2
(2017-09-28), IBM© SPSS© Statistics, Version 24, © Copyright
1989, 2016 SPSS Inc., an IBM Company and SAS version 9.4
[TS1M3] Copyright © 2002 by SAS Institute Inc., Cary, NC, USA.
RESULTS
Patients and Serum 25(OH)D Levels
Data from all 51 RRMS and 2 CIS patients recruited into the
EVIDIMS trial were used for this study. The mean age of patients
was 43 ± 10.2 years with 37 (69.8 %) females and a mean disease
duration of 9± 9.3 years.
The median (25, 75% Q) serum 25(OH)D was 18 ng/ml
(12, 24), signifying overall VD deficiency (Table 1). After
dichotomization by serum 25(OH)D< 30 vs. ≥ 30 ng/ml, 48 out
of 53 patients (91%) had 25(OH)D < 30 ng/ml with a median
(25, 75% Q) of 15 ng/ml (10, 21) in the < 30 ng/ml group while
TABLE 1 | Baseline characteristics of 51 RRMS and 2 CIS patients recruited in
the EVIDIMS Trial.
Variable Total
Female n [%] 37 (69.8)
Age in years [mean ± SD] 43 ± 10.2
Disease duration in years [mean ± SD] 9 ± 9.3
Serum 25 (OH) [med (25, 75% quartiles)] ng/ml 18 (12, 24)
EDSS [med (25,75% quartiles)] 2.0 (1.5, 3.0)
T2 lesion count [med (25,75% quartiles)] 55 (33, 84)
T2 lesion vol (ml) [med (25,75% quartiles)] 4 (2, 9)
TABLE 2 | Characteristics of patients with 25(OH)D levels < 30 vs. ≥ 30 ng/ml.
Subgroup analysis of 25(OH)D levels < 30 vs. ≥ 30 ng/ml
Variable < 30ng/ml
(n = 48)
≥ 30ng/ml
(n = 5)
p-value1
Age in years [mean ±
SD]
42.9 ± 10.1 39 ± 12.8 0.46
Disease duration in
years [mean ± SD]
9.6 ± 6.7 5.7 ± 5.4 0.15
Serum 25(OH) [med
(25, 75% quartiles)]
ng/ml
15 (10, 21) 33 (33, 35) <0.001
EDSS [med (25, 75%
quartiles)]
2.5 (1.5, 3) 1.0 (1, 2) 0.04
T2 lesion count [med
(25, 75% quartiles)]
60 (36, 84) 25 (24,33) 0.03
T2 lesion vol (ml) [med
(25, 75% quartiles)]
4 (2, 10) 2 (2, 3) 0.13
Gray matter vol (ml)
[med (25, 75%
quartiles)]
597 (553, 620) 594 (557, 652) 0.63
White matter
volume(ml) [med (25,
75% quartiles)]
536 (509, 591) 567 (547, 570) 0.49
Brain volume(ml) [med
(25, 75% quartiles)]
1126 (1063, 1209) 1161 (1114, 1222) 0.53
1Mann–Whitney test.
the remaining 5 out of 53 patients (9%) had 25(OH)D≥ 30 ng/ml
with a median of 33 (33, 35) ng/ml (p< 0.001) (Table 2).
Association of Serum 25(OH)D and
Disability Scores
In the entire cohort, there was an inverse association between
EDSS score and serum 25(OH)D level. The results remained the
same after adjustment for age, sex, and disease duration in a
multivariate analysis (simple: R2 = 0.10, p = 0.02; adjusted: R2
= 0.34, p < 0.001) (Figure 1). EDSS was higher in patients with
deficient (< 30 ng/ml) 25(OH)D: 2.5 (1.5, 3) compared to 1.0 (1,
2) for vitamin levels ≥ 30 ng/ml (p = 0.04) (Table 2). There was
no collinearity between the predictor variables tested.
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FIGURE 1 | Linear regression analysis of EDSS scores to serum vitamin D levels in the entire cohort with 95% confidence limits. Simple Linear regression showed a
significant association between EDSS scores and serum 25(OH)D levels (p = 0.02), which was confirmed after adjustment for age, sex, and disease duration in
multiple linear regression analysis (adjusted p < 0.001).
Association of Serum 25(OH)D and MRI
Parameters
The median (25, 75% Q) T2 weighted lesion count was 25 (24,
33) in the ≥ 30 ng/ml group, compared to 60 (36, 84) in the <
30 ng/ml group (p = 0.03; adjusted for age, gender, 25(OH)D
levels, and disease duration: p< 0.001). The numerical difference
in median T2 lesion volume [2 (2, 3) ml in the≥ 30 ng/ml group;
4 (2, 10) ml in the < 30 ng/ml group] was not significant [p
= 0.13; adjusted for age, gender, 25(OH)D levels, and disease
duration: p = 0.06] (Table 2). We found no association of serum
vitamin D levels with gray matter, white matter, and total brain
volumes (Table 2).
DISCUSSION
Using baseline characteristics of patients recruited in the
EVIDIMS trial, we show that according to the definitions of
the American Society of Medicine and the Japan Endocrine
Society (22, 23, 27), VD deficiency is common in RRMS/CIS
patients living in the north-eastern part of Germany. Moreover,
the range of serum levels and the proportions of serum VD levels
is in line with previously published MS cohorts. In this cohort,
VD deficiency showed an inverse association with measures of
disability and was furthermore linked to a higher T2w lesion
count but was not associated with T2 lesion volume, total brain
volume as well as gray and white matter volumes.
A high prevalence of VD deficiency in MS patients has been
demonstrated in other studies: In an earlier study on a different
patient cohort, we reported VD deficiency already in very early
phases of MS (5). A cross-sectional study of 50 RRMS patients
revealed a VD deficiency with a mean of 22.3 ng/ml /ml (42). In
a Moroccan study of 113MS patients, 97.3% of patients were VD
deficient with a mean of 11.69 ng/ml (43). There is an ongoing
debate whether VD deficiency represents a risk factor for MS or
whether this association is rather due to reverse causality, i.e., low
VD levels are a result of MS, for example as a consequence of
reduced outdoor activities. The fact that the cohort investigated
here was relatively young with a rather mild disability status
may be an argument against reverse causality. Moreover, in an
earlier study on a different cohort of early MS or CIS patients
we also observed VD deficiency already in very early phases of
MS (5) which also supports the interpretation that VD deficiency
is rather a cause than a consequence of MS.
Also, the inverse association between disability measures
and serum 25(OH)D levels demonstrated here are in
line with previous reports: a population-based study on
136MS patients from Australia showed that patients with
higher disability (EDSS > 3) had a higher probability of
insufficient vitamin D levels (44). Similarly, a cross-sectional
study on 267MS patients revealed an inverse association
between EDSS scores and serum 25(OH)D levels in the entire
cohort (45).
The association of deficient serum vitamin D levels with
MRI activity is controversial. While some studies could not
show any associations between serum 25(OH)D levels and
MRI activity (46) others showed that the development of
T2w or contrast enhancing lesions is correlated to the VD
serum level (47). Our MRI data support the association of
MRI activity and VD status. We, however, did not detect any
association between VD levels and measures of both global and
regional brain atrophy. Although speculative, this might well
be due to the small sample size and the low power to detect
such associations.
Taken together, our results confirm the high prevalence of
VD deficiency in MS patients and the possible associations it
has with MRI and clinical disease activity. Of note, causality or
directionality of these associations cannot be inferred from ours
and other cross-sectional studies reporting similar associations.
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Specifically, it is possible that reduced VD leads to a more severe
disease course. Alternatively, it may also be possible that higher
disability may lead to lower VD levels, e.g., by less physical
activity and reduced sunlight exposure. Previously, we reported
reduced VD levels in a cohort of very early MS/CIS patients
with low disability, which makes the latter less likely, but not
impossible. Our study, however, has some important limitations:
first, the overall small sample size and particularly the very
small number of patients in the VD sufficient group result in
a low power to detect associations. Secondly, our analyses are
based solely on the cut-offs for deficient and sufficient serum
VD levels defined for osteoporosis and normal health which
may not be generalized to the MS population. Additionally, we
only investigated patients from a particular area of Germany
which increased the homogeneity of our sample on the one
side but on the other side might not be representative for
MS patients in general. Finally, as serum samples were taken
throughout the year, seasonal variations of VD levels may
confound data.
In conclusion, the EVIDIMS cohort is representative of a
typical RRMS cohort with VD deficiency, we confirm previous
associations of low serum VD with clinical and disease activity
which provides further support for the role of VD in the
development and progression of MS.
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